Dengue vaccine

Kathryn Dzintars, PharmD, BCPS
Dengue vaccine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

VACCINE TYPE

  • Dengvaxia®, or the Dengue Tetravalent Vaccine, is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3 and 4.
    • Approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection AND who lived in an endemic area.
    • The vaccine is built on a yellow fever backbone component.

-- To view the remaining sections of this topic, please or --

VACCINE TYPE

  • Dengvaxia®, or the Dengue Tetravalent Vaccine, is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3 and 4.
    • Approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection AND who lived in an endemic area.
    • The vaccine is built on a yellow fever backbone component.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 17, 2023